10 Non‑reclosable packages (1) Subject to subsection 10(2), if a medicine to which this Order applies is in a non‑reclosable package, the package must be in the form of a blister or other sealed unit formed from paper, film, plastic material, metal foil or other sheet or strip material, or a combination of these materials in which a single dosage unit is enclosed, whether as part of a continuous series comprising a strip or sheet of the same material or not.
(2) A non‑reclosable package referred to in subsection 10(1) must not be formed from cellulose film or unlaminated paper.
(section 6)
Note 1 Class names reflect the Anatomical Therapeutic Chemical (ATC) classification system of the World Health Organization Collaborating Centre for Drug Statistics Methodology (http://www.whocc.no/atcddd/). Classes shown include any substance included under the given ATC classification, unless the substance is specifically exempted from this Order.
Item | Class |
1 | ACE INHIBITORS |
2 | ALPHA AND BETA BLOCKING AGENTS |
3 | alpha-adrenoreceptor antagonists including phenoxybenzamine |
4 | ANESTHETICS, LOCAL |
5 | ANGIOTENSIN II ANTAGONISTS |
6 | ANTIARRHYTHMICS |
7 | ANTICHOLINERGICS |
8 | ANTI‑DEMENTIA DRUGS |
9 | ANTIDEPRESSANTS |
10 | ANTIEMETICS AND ANTINAUSEANTS |
11 | ANTIEPILEPTICS |
12 | ANTIHISTAMINES |
13 | ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON‑STEROIDS |
14 | ANTIMALARIALS, except doxycycline |
15 | ANTINEOPLASTIC AGENTS |
16 | ANTI‑PARKINSON DRUGS |
17 | ANTIPSYCHOTICS |
18 | ANTITHROMBOTIC AGENTS |
19 | BENZODIAZEPINE DERIVATIVES and BENZODIAZEPINE RELATED DRUGS |
20 | BETA BLOCKING AGENTS |
21 | CALCIUM CHANNEL BLOCKERS |
22 | CARDIAC GLYCOSIDES |
23 | CENTRALLY ACTING SYMPATHOMIMETICS |
24 | DIURETICS |
25 | ERGOT ALKALOIDS |
26 | MONOAMINE OXIDASE INHIBITORS |
27 | OPIOIDS |
28 | ORAL BLOOD GLUCOSE LOWERING DRUGS |
ALISKIREN.
AMBRISENTAN.
ANISE OIL, except:
(a) when packed in a container having a nominal capacity of 50 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 50 per cent or less of anise oil, or a combination of anise oil and any other essential oil named in this Part.
ASPIRIN.
Azadirachta indica (Neem), in a preparation for human dermal use containing more than 1 per cent of cold pressed neem seed oil.
BASIL OIL, except:
(a) when packed in a container having a nominal capacity of 25 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation or oil containing 5 per cent or less of methyl chavicol.
BAY OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of bay oil, or a combination of bay oil and any other essential oil named in this Part.
BOSENTAN.
BROMHEXINE.
CAJUPUT OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of cajuput oil, or a combination of cajuput oil and any other essential oil named in this Part.
CAMPHORATED OIL.
CAMPHOR, except:
(a) in a liquid preparation containing 2.5 per cent or less of camphor;
(b) in an essential oil containing 10 per cent or less of camphor, packed in a container having a nominal capacity of 25 millilitres or less and fitted with a restricted flow insert;
(c) in an essential oil packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(d) in rosemary oil, sage oil (Spanish), or lavandin oil as such.
Carapichea ipecacuanha (ipecacuanha).
CASSIA OIL, except in a preparation containing 2 per cent or less of cassia oil.
CHLORAL HYDRATE.
CILOSTAZOL.
CINEOLE, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert;
(b) in a preparation or oil containing 25 per cent or less of cineole; or
(c) in rosemary oil or camphor oil (white).
CINNAMON BARK OIL, except in a preparation containing 2 per cent or less of cinnamon bark oil.
CINNAMON LEAF OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of cinnamon leaf oil, or a combination of cinnamon leaf oil and any other essential oil named in this Part.
CLONIDINE.
CLOVE OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of clove oil, or a combination of clove oil and any other essential oil named in this Part.
COLCHICINE.
Deferasirox.
Dextromethorphan.
ETHANOL, in a mouthwash preparation containing more than 3 grams of ethanol in a single pack.
EUCALYPTUS OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of eucalyptus oil, or a combination of eucalyptus oil and any other essential oil named in this Part.
FLUORIDE SALTS, in a pack containing the equivalent of more than 100 milligrams of elemental fluorine.
GUAIFENESIN.
IRON COMPOUNDS, in a pack containing a total of more than 250 milligrams of elemental iron, except for divided preparations in which:
(a) the iron is compounded with one or more other active ingredients; and
(b) the amount of elemental iron per dosage unit is 5 milligrams or less.
However iron oxides that are present as an excipient, in either a divided preparation containing 10 milligrams or less of total iron oxides per dosage unit or an undivided preparation containing 1 per cent or less of total iron oxides, may be excluded from the calculation of elemental iron content.
Ivabradine.
Lanthanum.
Lenalidomide.
MARJORAM OIL, except:
(a) when packed in a container having a nominal capacity of 50 millilitres or less and fitted with a restricted flow insert, or
(b) in a preparation containing 50 per cent or less of marjoram oil, or a combination of marjoram oil and any other essential oil named in this Part.
MELALEUCA OIL, except:
(a) when packed in a container having a nominal capacity of 15 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 25 per cent or less of melaleuca oil, or a combination of melaleuca oil and any other essential oil named in this Part.
METHYL SALICYLATE, in a liquid preparation containing 5 per cent or more of methyl salicylate.
MINOXIDIL, in a liquid preparation or a preparation for oral administration.
MOUTHWASH preparations — see ETHANOL.
NICOTINE.
NUTMEG OIL, except:
(a) when packed in a container having a nominal capacity of 25 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 50 per cent or less of nutmeg oil, or a combination of nutmeg oil and any other essential oil named in this Part.
Oxymetazoline.
PARACETAMOL ‑ all solid dosage forms and liquid preparations.
PENNYROYAL OIL, except in a preparation containing 4 per cent or less of d‑pulegone.
Pentoxyverine.
PHENYLEPHRINE.
Pholcodine.
PODOPHYLLUM/PODOPHYLLOTOXIN.
POLYGALA SENEGA (Senega).
POTASSIUM SALTS, in a pack containing a total of more than 4000 milligrams of elemental potassium, except:
(a) in a divided preparation in which the amount of elemental potassium per dosage unit is 40 milligrams to less; or
(b) when the potassium is present in the form of glucosamine sulfate potassium chloride complex.
PSEUDOEPHEDRINE.
RILUZOLE.
SAGE OIL DALMATIAN, except in a preparation containing 4 per cent or less of thujone.
SALBUTAMOL.
SASSAFRAS OIL, except in a preparation containing 1 per cent or less of safrole.
STAR ANISE OIL, except:
(a) when packed in a container having a nominal capacity of 50 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 50 per cent or less of star anise oil, or a combination of star anise oil and any other essential oil named in this Part.
THEOPHYLLINE.
THYME OIL, except:
(a) when packed in a container having a nominal capacity of 25 millilitres or less and fitted with a restricted flow insert; or
(b) in a preparation containing 50 per cent or less of thyme oil, or a combination of thyme oil and any other essential oil named in this Part.
THYROXINE.
Varenicline.
WINTERGREEN OIL — see METHYL SALICYLATE.
XYLOMETAZOLINE.